TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21734163

Group type: EXPERIMENTAL
Intervention: Counterfactual seeking (choice to learn about foregone alternatives)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaginative thoughts about foregone options
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upward counterfactual thoughts
Number of subjects: 0
Study: 18926434

Group type: EXPERIMENTAL
Intervention: Conivaptan (20 mg loading dose followed by 2 successive 24-hour continuous infusions of 40, 80, or 120 mg/d)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg/d
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Conivaptan 80 mg/d
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 16292517

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery group (LSG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional surgery group (CSG)
Number of subjects: 40
Study: 12754014

Group type: EXPERIMENTAL
Intervention: Total arterial revascularization (Group 1)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard CABG (Group 2)
Number of subjects: 188
Study: 11005229

Group type: EXPERIMENTAL
Intervention: Spectral image analysis using the SpectraCube system for evaluating ER content.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Spectral image analysis for ER detection in cases scored as 0 by the pathologist's index.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Spectral image analysis in a test case scored as 1 by the pathologist's index.
Number of subjects: 13
Study: 8973993

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 10 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 20 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1456384

Group type: EXPERIMENTAL
Intervention: New slow-release preparation of valproic acid (SR-VPA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional preparation of valproic acid (C-VPA)
Number of subjects: 13
Study: 4074116

Group type: EXPERIMENTAL
Intervention: 1cm lift under left or right foot
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2cm lift under left or right foot
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 3cm lift under left or right foot
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4cm lift under left or right foot
Number of subjects: 14

Group type: COMPARATOR
Intervention: Barefoot condition (no lifts)
Number of subjects: 14
Study: 30820005

Group type: EXPERIMENTAL
Intervention: High-dose hemodialysis
Number of subjects: 919

Group type: COMPARATOR
Intervention: Standard-dose hemodialysis
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: High flux hemodialysis
Number of subjects: 919

Group type: COMPARATOR
Intervention: Low flux hemodialysis
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Low stable FGF23 trajectory
Number of subjects: 919

Group type: COMPARATOR
Intervention: Elevated stable FGF23 trajectory
Number of subjects: 919
Study: 29630570

Group type: EXPERIMENTAL
Intervention: Controlled Active Motion (CAM) therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous Passive Motion (CPM) therapy
Number of subjects: 50
Study: 26352863

Group type: EXPERIMENTAL
Intervention: Melatonin (1 or 3 mg nightly)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 25130678

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22787067

Group type: EXPERIMENTAL
Intervention: Full-dose polycap (plus K(+) supplementation)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Low-dose polycap
Number of subjects: 518
Study: 20150769

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Induction chemotherapy plus radiotherapy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Beclin 1 high expression
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: HIF-1alpha expression
Number of subjects: 128
Study: 17846268

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b, 250 microg subcutaneously every other day
Number of subjects: 404
Study: 15316509

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin sodium (5000 IU/mL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11471088

Group type: EXPERIMENTAL
Intervention: Trichiasis surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated trichiasis
Number of subjects: 0
Study: 9602202

Group type: COMPARATOR
Intervention: rhEPO 750 IU/kg/week (low-dose group)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: rhEPO 1500 IU/kg/week (high-dose group)
Number of subjects: 184
Study: 8030684

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (400 micrograms IV four times) and betamethasone (5 mg IM four times)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 2810410

Group type: EXPERIMENTAL
Intervention: Clindamycin dosed at 1,200 mg every 12 hours
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose amikacin (11 mg/kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 72-hour coverage
Number of subjects: 150
Study: 931851

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (produced by rebreathing a gas mixture of 6% CO2 in air)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading (rebreathing repeated during loading)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (normal breathing without hypoxia)
Number of subjects: 10
Study: 30016770

Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) 6-9 g/d for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA)
Number of subjects: 0
Study: 28882152

Group type: EXPERIMENTAL
Intervention: SPACE intervention (portable play equipment, staff training, modified outdoor playtime)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 195
Study: 26503196

Group type: EXPERIMENTAL
Intervention: Intermittent high-dose interferon alfa-2b (iHDI) 20 MIU/m2 administered intravenously 5 days a week for 4 weeks then repeated every 4 months
Number of subjects: 627

Group type: COMPARATOR
Intervention: Standard high-dose interferon alfa-2b (HDI)
Number of subjects: 627
Study: 23350686

Group type: EXPERIMENTAL
Intervention: Closure of parietal peritoneal layer (Group I)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-closure of parietal peritoneal layer (Control, Group II)
Number of subjects: 110
Study: 21816683

Group type: EXPERIMENTAL
Intervention: Cognitive intervention and exercise program
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lumbar fusion
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 19030864

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD) therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (nonsteroidal anti-inflammatory drug, physical therapy, and therapeutic exercise program)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups (MLD and control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MLD group
Number of subjects: 34
Study: 16127567

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg q.d.), tetracycline (500 mg q.i.d.), and furazolidone (200 mg t.i.d.) for 7 days (LTF; n = 52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week, plus azithromycin (500 mg q.d.) for the first 3 days (LAAz; n = 52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg q.d.), tetracycline (500 mg q.i.d.), and furazolidone (200 mg t.i.d.) for 7 days (LTF)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week, plus azithromycin (500 mg q.d.) for the first 3 days (LAAz)
Number of subjects: 104
Study: 14601489

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 30
Study: 10660161

Group type: EXPERIMENTAL
Intervention: Stentless aortic valve replacement (Freestyle, Toronto, n = 106)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional biological aortic valve replacement (Carpentier‐Edwards, n = 74)
Number of subjects: 180
Study: 8535227

Group type: COMPARATOR
Intervention: CHOP (doxorubicin)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: CIOP (idarubicin)
Number of subjects: 115
Study: 1971641

Group type: EXPERIMENTAL
Intervention: Cefotaxime (2 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mueller-Hinton medium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Capsule medium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Protein binding effect
Number of subjects: 12
Study: 474480

Group type: EXPERIMENTAL
Intervention: Hemicellulose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cellulose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pectin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Basal diet alone
Number of subjects: 8
Study: 31674644

Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Placebo (ACTIVE) to Alendronate (ACTIVExtend)
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Abaloparatide to Alendronate
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Nonvertebral fractures and clinical fractures
Number of subjects: 1139
Study: 30055002

Group type: EXPERIMENTAL
Intervention: School support intervention (school uniforms, school fees, and nurse visits)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Control group (no school support intervention)
Number of subjects: 835
Study: 27386814

Group type: EXPERIMENTAL
Intervention: Game-based constraint-induced movement therapy (CIMT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: General game-based training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 36
Study: 25847478

Group type: EXPERIMENTAL
Intervention: NT‐proBNP levels at baseline
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Each higher quartile of NT‐proBNP
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Adjusted hazard ratio for NT‐proBNP after adding clinical AF burden
Number of subjects: 296
Study: 23413135

Group type: EXPERIMENTAL
Intervention: l-arginine aspartate 8 g combined with 200 mg of adenosine monophosphate (AA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study: 21198364

Group type: EXPERIMENTAL
Intervention: Traditional control scheme (Playstation 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: More technologically advanced control scheme (Nintendo Wii)
Number of subjects: 0
Study: 19954529

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 200 mg bid for 28 days (1-3 years old) or 400 mg bid for 28 days (4-11 years old)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Nitazoxanide and Placebo)
Number of subjects: 60
Study: 17382741

Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil for 6 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 5/20 mg tadalafil for 12 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 5/20 mg tadalafil with placebo run-in for 12 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 5/20 mg tadalafil for sexually active men with erectile dysfunction
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 15220016

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 749

Group type: COMPARATOR
Intervention: NPH
Number of subjects: 749
Study: 11450709

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: COMPARATOR
Intervention: Weight maintenance (control group)
Number of subjects: 38
Study: 9506326

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 15
Study: 8190206

Group type: EXPERIMENTAL
Intervention: Cognitive impairment screening using the Information/Orientation Section of the Clifton Assessment Procedure with a cutoff point of 7.
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Univariate analysis of associated factors for cognitive impairment.
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of associated factors for cognitive impairment.
Number of subjects: 2011
Study: 3169109

Group type: EXPERIMENTAL
Intervention: Inhaled gallopamil 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral diltiazem 120 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31697371

Group type: EXPERIMENTAL
Intervention: Mobile neurofeedback for three months
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mobile neurofeedback sessions (mean of 33.09 sessions, 10 minutes each)
Number of subjects: 41
Study: 29984137

Group type: EXPERIMENTAL
Intervention: Community health worker intervention (4 educational workshops and 4 one-on-one visits over 4 months)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (1 educational workshop)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 240
Study: 28756068

Group type: EXPERIMENTAL
Intervention: Iclaprim 0.8 mg/kg IV q12h
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Iclaprim 1.2 mg/kg IV q8h
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vancomycin 1 g IV q12h
Number of subjects: 70
Study: 26164092

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (Group A) including pedometers, website for step registration, physical activity on prescription, motivational interviewing (10 occasions), and group consultations (12 occasions)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Pedometer intervention (Group B) including pedometers and website for step registration
Number of subjects: 310

Group type: COMPARATOR
Intervention: Usual care (Control Group C)
Number of subjects: 310
Study: 22235792

Group type: EXPERIMENTAL
Intervention: CT group
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CBCT group
Number of subjects: 11

Group type: COMPARATOR
Intervention: Comparison between CT and CBCT groups
Number of subjects: 11
Study: 20069307

Group type: EXPERIMENTAL
Intervention: 6.25 mg bupivacaine alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3.75 mg bupivacaine, 25 mg mepivacaine and 0.0125 mg epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Systemic painkillers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Local anaesthetics (bupivacaine and mixture)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epinephrine infiltration
Number of subjects: 30
Study: 18821691

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 4 weeks for 24 weeks
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus DMARDs
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1220
Study: 16178659

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Peritoneal dialysis
Number of subjects: 120
Study: 12439771

Group type: EXPERIMENTAL
Intervention: Living high-training low (LHTL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Living low-training low (CONTROL)
Number of subjects: 21
Study: 10353583

Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (1600 microg four times daily)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 7728627

Group type: EXPERIMENTAL
Intervention: Active chiropractic spinal manipulative treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham chiropractic spinal manipulative treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both interventions (active and sham)
Number of subjects: 31
Study: 2045756

Group type: EXPERIMENTAL
Intervention: Italian coffee
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 200 mg purified caffeine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (highly decaffeinated coffee for regular coffee, and china bitter extract for caffeine)
Number of subjects: 15
Study: 7299084

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 120

Group type: COMPARATOR
Intervention: No Counseling (Control)
Number of subjects: 120
Study: 30916531

Group type: EXPERIMENTAL
Intervention: Afferent electrical stimulation with mirror therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham afferent electrical stimulation with sham mirror therapy
Number of subjects: 30
Study: 28658119

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 66
Study: 25781618

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 60
Study: 24106771

Group type: EXPERIMENTAL
Intervention: Training group 1 (TG1, n=282) performing supervised strength training from February to June 2009
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Training group 2 (TG2, n=255) performing supervised strength training from August to December 2009
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Subgroup analyses among those with severe pain (>=3 on a scale of 0-9)
Number of subjects: 537
Study: 21354681

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate, 0.3 μg/kg
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 19383030

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) (800-1000 kcal/day)
Number of subjects: 111
Study: 17364459

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finasteride 5 mg/day
Number of subjects: 0
Study: 15582073

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 31
Study: 11892367

Group type: EXPERIMENTAL
Intervention: Button Pull Group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Non‐Button Pull Group
Number of subjects: 91
Study: 11192135

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 9127332

Group type: EXPERIMENTAL
Intervention: IgG1/IgG clearance ratio
Number of subjects: 34

Group type: COMPARATOR
Intervention: PA/SA clearance ratio
Number of subjects: 34

Group type: COMPARATOR
Intervention: IgG1/IgG2 clearance ratio
Number of subjects: 34
Study: 1300901

Group type: EXPERIMENTAL
Intervention: Surgical drainage after thyroidectomy
Number of subjects: 97

Group type: COMPARATOR
Intervention: No surgical drainage after thyroidectomy
Number of subjects: 97
Study: 3895365

Group type: EXPERIMENTAL
Intervention: Bornaprine 8 mg/die
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29804955

Group type: EXPERIMENTAL
Intervention: In-office diagnostic arthroscopy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 110
Study: 27594130

Group type: EXPERIMENTAL
Intervention: Oral direct factor Xa inhibitors
Number of subjects: 57497

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 57497
Study: 24779706

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 5423

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 5423

Group type: EXPERIMENTAL
Intervention: Obesity and IFG after excluding underweight individuals (BMI <22 kg/m(2)) and smokers
Number of subjects: 5423
Study: 22879450

Group type: EXPERIMENTAL
Intervention: Multiple-step strategy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Single-step strategy
Number of subjects: 95
Study: 20977339

Group type: EXPERIMENTAL
Intervention: HPV-16 positive women with intervening negativity for HPV-16 (n=11)
Number of subjects: 86

Group type: COMPARATOR
Intervention: HPV-16 positive women who consistently tested positive (n=49)
Number of subjects: 86
Study: 18568578

Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg/day)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 377
Study: 15890074

Group type: COMPARATOR
Intervention: Single dosage of memantine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ascending dosage of memantine over 8 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12381242

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate
Number of subjects: 423
Study: 10073852

Group type: EXPERIMENTAL
Intervention: COER-24 verapamil 240 mg titrated to 480 mg at bedtime (n = 173)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg titrated to 10 mg/day (n = 149)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg plus atenolol 50 mg/day in the A.M. (n = 154)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo (n = 75)
Number of subjects: 551
Study: 7727580

Group type: EXPERIMENTAL
Intervention: Individuals aged 16‐20
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Adults aged 21 and over
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 800
Study: 2390587

Group type: EXPERIMENTAL
Intervention: Informed consent for trial participation
Number of subjects: 3054

Group type: EXPERIMENTAL
Intervention: Refusal to participate in trials
Number of subjects: 3054

Group type: EXPERIMENTAL
Intervention: Mastectomy treatment
Number of subjects: 3054

Group type: EXPERIMENTAL
Intervention: Exclusion from trials
Number of subjects: 3054
Study: 29178536

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-unsaturated/low-saturated fat diet (LC)
Number of subjects: 115

Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat diet (HC)
Number of subjects: 115